New Study: Cannabis Can Slow, Cure Alzheimer’s Disease

“A new study conducted by researchers at the Roskamp Institute in Florida, and published in the journal Molecular and Cellular Neuroscience, has found that cannabis can slow the effects of Alzheimer’s Disease, and may in fact be able to halt it entirely.”

MMMA LEAF AND SYMBOL_full

“According to Corbin Bachmeier, Ph.D – who’s the lead researcher of the study – Alzheimer’s Disease is “the result of impaired Aβ [Amyloid-β protein] clearance from the brain”. According to this study, cannabis can solve this problem, making it a potential treatment…

This research validates past studies (including some presented earlier this year, as well as a 2006 study), though is the first to actually explain why cannabis can be beneficial to the disease.”

More: http://thejointblog.com/new-study-cannabis-can-slow-cure-alzheimers-disease/#more-7683

Marijuana: Miracle Cure For Crohn’s Disease?

“Crohn’s disease is a autoimmunity deficiency in the gastronomical tract that can cause anything from mild stomach pains to vomiting and in extreme cases, chronic bloody diarrhea. There’s no cure for the disorder but now, researchers in Israel say they’ve found evidence that marijuana causes complete remission of the disease.

This news comes the Meir Medical Center in Israel, which treated 21 patients suffering from Crohn’s disease. 11 of the patients smoked two joints per day of cannabis sativa, which the researchers believed would provide anti-inflammatory relief, while the other (unlucky) 10 were only given a placebo. “The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but this has not been investigated in controlled trials,” the researchers argued. “We performed a prospective trial to determine whether cannabis can induce remission in patients with Crohn’s disease.”

Five of the 11 patients who smoked the weed, the study, which was published in the U.S. National Library of Medicine, states, acheived “total remission” of their disease, whereas only four of the 10 patients who didn’t smoke the pot reported only slight improvement of their condition. Needless to say, the study, while promising, only seems to suggest that more research should be undertaken. “Further studies, with larger patient groups and a nonsmoking mode of intake, are warranted,” the scientists argued.”

 http://blogs.ocweekly.com/navelgazing/2013/07/marijuana_miracle_cure_for_cro.php

[From cannabis to selective CB2R agonists: molecules with numerous therapeutical virtues].

“Originally used in Asia for the treatment of pain, spasms, nausea and insomnia, marijuana is the most consumed psychotropic drug worldwide. The interest of medical cannabis has been reconsidered recently, leading to many scientific researches and commercialization of these drugs.

Natural and synthetic cannabinoids display beneficial antiemetic, anti-inflammatory and analgesic effects in numerous diseases, however accompanied with undesirable effects due to the CB1 receptor. Present researches focus on the design of therapeutical molecules targeting the CB2 receptors, and thus avoiding central side effects and therefore psychotropic effects caused by the CB1 receptor.”

http://www.ncbi.nlm.nih.gov/pubmed/23732102

MARIJUANA THC May Actually Help Protect YOUR BRAIN Against Injury, According to a New Study

“Studies show that the THC in the plant has many therapeutic qualities…

Marijuana’s THC may be beneficial to humans.

Marijuana may actually help protect the brain against injury, a new study suggests.

Sarne said the study suggests that THC could be used to prevent brain injury or treat brain trauma.

Researchers believe that the THC treatment works by causing minute damage to the brain to build resistance and trigger protective measures in the face of much more severe injury.”

More: http://www.kpopstarz.com/articles/29846/20130602/marijuana-thc-may-help-protect-brain-from-injury.htm

Medical Cannabis Treatment for Cancer and HIV/AIDS ?

“Benefits of Medical Cannabis”

medical marijuana

“Today, there are at least 17 states, including the District of Colombia, where cannabis is legal. Ohio, South Carolina, Colorado, New Jersey, California, and Michigan are just a few states that garnered strong support in the legalization of  medical cannabis. In Illinois, a bill legalizing the use of  cannabis needed the signature of Gov Pat Quinn. The legislation was approved by House and Senate, permitting doctors to prescribe cannabis for cancer and patients with HIV/AIDS and other diseases…

There is now quantifiable evidence that cannabis is beneficial in treating many disorders…

Moreover, the Medical Cannabis Research and the University of California found out that cannabis can treat HIV/AIDS and multiple sclerosis symptoms. It can even benefit cancer patients to mitigate the unpleasant side effects of chemotherapy or as an alternative treatment for cervical cancer, breast cancer, prostate cancer, lung cancer, colorectal cancer, brain cancer, and leukemia.”

More: http://guardianlv.com/2013/05/medical-cannabis-treatment-for-cancer-and-hivaids/

Study Suggests Marijuana Mitigates Symptoms Of Crohn’s Disease

 

More and more, researchers are investigating the beneficial effects of marijuana on a variety of diseases. In Clinical Gastroenterology and Hepatology this week, researchers in Israel reported their findings from a study of how cannabis affects patients with Crohn’s disease.

Cannabis sativa has been reported to benefit inflammatory bowel diseases, the researchers wrote. The team wanted to see if it was possible to induce remission in Crohn’s patients through cannabis treatment…

… a short course (8 weeks) of THC-rich cannabis produced significant clinical, steroid-free benefits to 11 patients with active CD, compared to placebo, without side effects,” the team wrote. “Further studies, with larger patient groups and a non-smoking mode of intake, are warranted.”

Read more: http://www.medicaldaily.com/articles/15508/20130514/marijuana-thc-crohnsdisease-cannabis.htm

Cannabis Induces a Clinical Response in Patients with Crohn’s Disease: a Prospective Placebo-Controlled Study.

“The marijuana plant Cannabis sativa has been reported to produce beneficial effects for patients with inflammatory bowel diseases, but these have not been investigated in controlled trials. We performed a prospective trial to determine whether cannabis can induce remission in patients with Crohn’s disease…

Complete remission was achieved by 5/11 subjects in the cannabis group (45%)… Three patients in the cannabis group were weaned from steroid dependency. Subjects receiving cannabis reported improved appetite and sleep, with no significant side effects.

CONCLUSION:

Although the primary endpoint of the study (induction of remission) was not achieved, a short course (8 week) of THC-rich cannabis produced significant clinical, steroid-free benefits to 11 patients with active CD, compared to placebo, without side effects.

Further studies, with larger patient groups and a non-smoking mode of intake, are warranted. ClinicalTrials.gov NCT01040910.”

http://www.ncbi.nlm.nih.gov/pubmed/23648372

Overexpression of cannabinoid receptors CB1 and CB2 correlates with improved prognosis of patients with hepatocellular carcinoma.

“CB1 and CB2 are multifunctional cannabinoid-specific receptors considered to be involved in inhibition of tumor development…

To elucidate their roles in hepatocarcinogenesis, we analyzed the expression of these receptors in tumor and matched nontumorous tissues of human hepatocellular carcinoma (HCC) samples.

Our results indicate that CB1 and CB2 have potential as prognostic indicators and suggest possible beneficial effects of cannabinoids on prognosis of patients with HCC.”

http://www.ncbi.nlm.nih.gov/pubmed/17074588

Cannabinoid Receptor 2-Mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells

“Agents that activate cannabinoid receptor pathways have been tested as treatments for cachexia, nausea or neuropathic pain in HIV-1/AIDS patients… Cannabinoid agonists activate the CB1R and CB2R cannabinoid receptors…

Cannabinoid agonists are currently under investigation for the treatment of AIDS-associated cachexia, nausea, and neuropathic pain. One such drug, dronabinol (Δ9-THC; Marinol®), has won Food and Drug Administration (FDA) approval for treatment of HIV-associated anorexia. Additionally, the prescription of smoked or ingested cannabis (marijuana) for treatment of AIDS-related symptoms has been approved…. Despite the use of cannabinoids by HIV/AIDS patients, few studies have investigated the impact of such drugs in regard to viral pathogenesis or immune regulation…

….Indeed, both smoked marijuana and dronabinol were reported to increase total CD4+ T cell number and naïve T cell number over a 21-day period. A decrease in viral load was also observed in these patients. Similarly, in SIV infected rhesus macaques, Δ9-THC exposure reduced viral load and CD4+ T cell depletion, significantly increasing animal survival over an 11 month period.

. Our findings suggest that CB2R activation in CD4+ T cells can inhibit actin reorganization and impair productive infection following cell-free or cell-associated viral acquisition of CXCR4-tropic HIV-1 in resting cells.

Therefore, the clinical use of CB2R agonists in the treatment of AIDS symptoms may also exert beneficial adjunctive antiviral effects against CXCR4-tropic viruses in late stages of HIV-1 infection.

Further study of cannabinoids and other neuroendocrine regulators that selectively modulate immune function may result in the discovery of new anti-viral drugs that can also mitigate AIDS-associated symptoms.”

Full text: http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309010/

The effects of cannabidiol on the antigen-induced contraction of airways smooth muscle in the guinea-pig.

“(-)-Δ(9)-Tetrahydrocannabinol has been demonstrated to have beneficial effects in the airways, but its psychoactive effects preclude its therapeutic use for the treatment of airways diseases. In the present study we have investigated the effects of (-)-cannabidiol, a non-psychoactive component of cannabis for its actions on bronchial smooth muscle in vitro and in vivo.

 Guinea-pig bronchial smooth muscle contractions induced by exogenously applied spasmogens were measured isometrically. In addition, contractile responses of bronchial smooth muscle from ovalbumin-sensitized guinea-pigs were investigated in the absence or presence of (-)-cannabidiol. Furthermore, the effect of (-)-cannabidiol against ovalbumin-induced airway obstruction was investigated in vivo in ovalbumin-sensitized guinea pigs. (-)-Cannabidiol did not influence the bronchial smooth muscle contraction induced by carbachol, histamine or neurokinin A. In contrast, (-)-cannabidiol inhibited anandamide- and virodhamine-induced responses of isolated bronchi. A fatty acid amide hydrolase inhibitor, phenylmethanesulfonyl fluoride reversed the inhibitory effect of (-)-cannabidiol on anandamide-induced contractions. In addition, (-)-cannabidiol inhibited the contractile response of bronchi obtained from allergic guinea-pigs induced by ovalbumin. In vivo, (-)-cannabidiol reduced ovalbumin-induced airway obstruction.

 In conclusion, our results suggest that cannabidiol can influence antigen-induced airway smooth muscle tone suggesting that this molecule may have beneficial effects in the treatment of obstructive airway disorders.”

http://www.ncbi.nlm.nih.gov/pubmed/23428645